Moreover, in pre-clinic ovarian cancer studies, RAD50 expression resulted higher in platinum-resistant cells [80], and platinum treatment increased nuclear sub-cellular localization of NBS1 [78] and RAD50 [80] more in platinum-resistant cells with respect to the sensitive ones, supporting the idea that accumulation of nuclear MRN proteins could contribute to cisplatin resistance in this tumor background. The gene discussed is RAD50; the disease is neoplasm.